CD133+ cells isolated from various sources and their role in future clinical perspectives

Mirella Meregalli, Andrea Farini, Marzia Belicchi, Yvan Torrente

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background. CD133 is a member of a novel family of cell surface glycoproteins. Initially, the expression of CD133 antigen was seen only in the hematopoietic derived CD34+ stem cells. At present, CD133 expression is demonstrated in undifferentiated epithelium, different types of tumors and myogenic cells. CD133+ neurosphere cells isolated from brain are able to differentiate into both neurons and glial cells. These data suggested that CD133 could be a specific marker for various stem and progenitor cell populations. Objectives. The main goal would be to describe the role for CD133 as a marker of stem cells able to engraft and differentiate, to form functional non-hematopoietic adult lineages and contribute to disease amelioration via tissue regeneration. Results/conclusion. In conclusion, since the rise of CD133 antigen as a suitable stem cell marker, the possible use of CD133+ stem cells in therapeutic applications has opened a new promising field in the treatment of degenerating diseases. The human circulating cells expressing the CD133 antigen behave as a stem cell population capable of commitment to hematopoietic, endothelial and myogenic lineages. CD133 cell therapy may represent a promising treatment for many diseases.

Original languageEnglish
Pages (from-to)1521-1528
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Stem cells
Stem Cells
Antigens
Cells
Tissue regeneration
Membrane Glycoproteins
Neurons
Tumors
Brain
Cell- and Tissue-Based Therapy
Neuroglia
Population
Regeneration
Therapeutics
Epithelium
AC133 Antigen
Neoplasms

Keywords

  • CD133
  • DMD
  • Prominin-1
  • Stem cells

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

CD133+ cells isolated from various sources and their role in future clinical perspectives. / Meregalli, Mirella; Farini, Andrea; Belicchi, Marzia; Torrente, Yvan.

In: Expert Opinion on Biological Therapy, Vol. 10, No. 11, 11.2010, p. 1521-1528.

Research output: Contribution to journalArticle

@article{1d220bf334a946a2b6165da490b8a1f7,
title = "CD133+ cells isolated from various sources and their role in future clinical perspectives",
abstract = "Background. CD133 is a member of a novel family of cell surface glycoproteins. Initially, the expression of CD133 antigen was seen only in the hematopoietic derived CD34+ stem cells. At present, CD133 expression is demonstrated in undifferentiated epithelium, different types of tumors and myogenic cells. CD133+ neurosphere cells isolated from brain are able to differentiate into both neurons and glial cells. These data suggested that CD133 could be a specific marker for various stem and progenitor cell populations. Objectives. The main goal would be to describe the role for CD133 as a marker of stem cells able to engraft and differentiate, to form functional non-hematopoietic adult lineages and contribute to disease amelioration via tissue regeneration. Results/conclusion. In conclusion, since the rise of CD133 antigen as a suitable stem cell marker, the possible use of CD133+ stem cells in therapeutic applications has opened a new promising field in the treatment of degenerating diseases. The human circulating cells expressing the CD133 antigen behave as a stem cell population capable of commitment to hematopoietic, endothelial and myogenic lineages. CD133 cell therapy may represent a promising treatment for many diseases.",
keywords = "CD133, DMD, Prominin-1, Stem cells",
author = "Mirella Meregalli and Andrea Farini and Marzia Belicchi and Yvan Torrente",
year = "2010",
month = "11",
doi = "10.1517/14712598.2010.528386",
language = "English",
volume = "10",
pages = "1521--1528",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - CD133+ cells isolated from various sources and their role in future clinical perspectives

AU - Meregalli, Mirella

AU - Farini, Andrea

AU - Belicchi, Marzia

AU - Torrente, Yvan

PY - 2010/11

Y1 - 2010/11

N2 - Background. CD133 is a member of a novel family of cell surface glycoproteins. Initially, the expression of CD133 antigen was seen only in the hematopoietic derived CD34+ stem cells. At present, CD133 expression is demonstrated in undifferentiated epithelium, different types of tumors and myogenic cells. CD133+ neurosphere cells isolated from brain are able to differentiate into both neurons and glial cells. These data suggested that CD133 could be a specific marker for various stem and progenitor cell populations. Objectives. The main goal would be to describe the role for CD133 as a marker of stem cells able to engraft and differentiate, to form functional non-hematopoietic adult lineages and contribute to disease amelioration via tissue regeneration. Results/conclusion. In conclusion, since the rise of CD133 antigen as a suitable stem cell marker, the possible use of CD133+ stem cells in therapeutic applications has opened a new promising field in the treatment of degenerating diseases. The human circulating cells expressing the CD133 antigen behave as a stem cell population capable of commitment to hematopoietic, endothelial and myogenic lineages. CD133 cell therapy may represent a promising treatment for many diseases.

AB - Background. CD133 is a member of a novel family of cell surface glycoproteins. Initially, the expression of CD133 antigen was seen only in the hematopoietic derived CD34+ stem cells. At present, CD133 expression is demonstrated in undifferentiated epithelium, different types of tumors and myogenic cells. CD133+ neurosphere cells isolated from brain are able to differentiate into both neurons and glial cells. These data suggested that CD133 could be a specific marker for various stem and progenitor cell populations. Objectives. The main goal would be to describe the role for CD133 as a marker of stem cells able to engraft and differentiate, to form functional non-hematopoietic adult lineages and contribute to disease amelioration via tissue regeneration. Results/conclusion. In conclusion, since the rise of CD133 antigen as a suitable stem cell marker, the possible use of CD133+ stem cells in therapeutic applications has opened a new promising field in the treatment of degenerating diseases. The human circulating cells expressing the CD133 antigen behave as a stem cell population capable of commitment to hematopoietic, endothelial and myogenic lineages. CD133 cell therapy may represent a promising treatment for many diseases.

KW - CD133

KW - DMD

KW - Prominin-1

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=77958491624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958491624&partnerID=8YFLogxK

U2 - 10.1517/14712598.2010.528386

DO - 10.1517/14712598.2010.528386

M3 - Article

C2 - 20932225

AN - SCOPUS:77958491624

VL - 10

SP - 1521

EP - 1528

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 11

ER -